BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin

Reuters

2024/12/08

Dec 7 (Reuters) - Beam Therapeutics Inc :

* BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING

* BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

* BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2489221773"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489221773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489221773?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-08 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489221773","market":"us","top_or_hot":-1,"title":"BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin","media":"Reuters","content":"<html><body><p>Dec 7 (Reuters) - Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING</p><p>   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</p><p>   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-08 00:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Dec 7 (Reuters) - Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING</p><p>   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</p><p>   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2489221773","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489221773","pubTimestamp":1733589003,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 7  - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","LENZ":"Therapeutics","BK4588":"碎股","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"BRIEF-Beam Therapeutics表示，所有7名接受Beam-101治疗的患者均实现了胎儿血红蛋白的持久增加和镰状血红蛋白的减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BEAM":0.9},"content_text":"Dec 7 (Reuters) - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}